Diabetes Drug Helps Women with Ovary Disorder

It spurs ovulation, potentially boosting fertility

Please note: This article was published more than one year ago. The facts and conclusions presented may have since changed and may no longer be accurate. And "More information" links may no longer work. Questions about personal health should always be referred to a physician or other health care professional.

En Español

HealthDay Reporter

THURSDAY, June 17, 2004 (HealthDayNews) -- A drug commonly prescribed to help treat diabetes can also help improve symptoms of a hormonal disorder that can make women infertile.

The drug rosiglitazone (Avandia) helped women with polycystic ovary syndrome -- which is marked by infertility, acne, excess weight and excess hair -- to ovulate more frequently, said Dr. Nicholas Cataldo, adjunct clinical instructor of obstetrics and gynecology at Stanford University and lead author of the study.

The drug also helped improve insulin resistance, another problem with the disorder, in which the normal amount of insulin secreted by the pancreas cannot get to cells.

Cataldo presented the findings at the annual meeting of the Endocrine Society that runs from June 16-19 in New Orleans.

One in 15 women suffer from polycystic ovary syndrome, making it the most common endocrine disorder of reproductive-aged women in the United States.

"We picked a particularly insulin-resistant group," said Cataldo. His team treated 42 women for 12 weeks with either 2 milligrams, 4 or 8 milligrams of the drug.

"What we found is, as expected, the drug improved insulin resistance," said Cataldo. But it also helped with ovulation problems. "Fifty-five percent of the women ovulated at least once during the 12-week study."

"So the good news is, it can be used in an infertility clinic setting to promote ovulation without going to injectable drugs with the risk of multiple births," Cataldo said.

Symptoms of PCOS become apparent at or around puberty, and the symptoms vary greatly in severity. Women may have many symptoms or a few of them, such as acne, excess hair that grows in a male-like pattern on the chest, upper lip, chin and other areas, and excess weight. The ovulatory problems can lead to infertility. And the insulin resistance boosts the risk of type 2 diabetes. Women with untreated PCOS also have a higher risk of heart disease.

The idea to use a diabetes drugs to treat PCOS isn't new, Cataldo said, but rosiglitazone hasn't been studied extensively for PCOS. Another diabetes drug, metformin (Glucophage), has been found effective in reducing excess circulating male hormones and promoting ovulation, but not without side effects such as stomach problems.

In his study, the same side effects weren't reported, Cataldo said.

Dr. Guy Ringler, a reproductive endocrinologist in Los Angeles, and staff physician at Santa Monica UCLA Medical Center, lauded the new study. "I think this study is impressive and it shows [rosiglitazone] is a promising new agent for treatment of women with PCOS," he said.

"One of the problems with metformin is, it's not well-tolerated," Ringler said. "At least half will complain of GI complaints such as bloating, severe enough that they stop taking the medicine."

Despite the promising findings from the new study, Ringler said, a lot is yet to be learned.

"What we don't know is, should we be treating every woman with PCOS long-term with these insulin-sensitizing agents? And the question is can they prevent the long-term health complications such as development of type 2 diabetes and cardiovascular complications? And that has not been shown."

"If we could find a good agent that is safe in correcting some of the abnormalities and is well-tolerated, perhaps it will have usefulness in preventing long-term health problems associated with PCOS," Ringler said.

Dr. Tracey McLaughlin, a clinical instructor in the division of endocrinology at Stanford University and a co-author of the study, added that the new research "is showing there is another therapeutic option of fertility in women with PCOS."

More information

To learn more about PCOS, visit the American Society for Reproductive Medicine.

SOURCES: Nicholas A. Cataldo, M.D., adjunct clinical instructor of obstetrics and gynecology, Stanford University Medical Center, Palo Alto, Calif.; Tracey McLaughlin, M.D., clinical instructor, division of endocrinology, Stanford University Medical Center, Palo Alto, Calif.; Guy Ringler, M.D., reproductive endocrinologist, California Fertility Partners, Los Angeles; June 16, 2004, presentation, Endocrine Society annual meeting, New Orleans

Last Updated: